Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Biologic & Biosimilar RA Drugs Market Value Growth And Long-Term Outlook
The market for biologic & biosimilar RA drugs has experienced substantial growth in recent years. It will grow from $14.57 billion in 2025 to $15.55 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be attributed to factors such as the increasing prevalence of rheumatoid arthritis, a limited range of treatment options, growing investment in biologics research, increasing healthcare expenditure, and the patent expiry of key biologics.
The biologic & biosimilar ra drugs market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $20.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Factors driving this growth during the forecast period include the increasing uptake of biosimilars, advancements in drug delivery technologies, expanded manufacturing capabilities, supportive regulatory frameworks for biologics, and heightened awareness regarding precision medicine. Key trends expected during this period encompass personalized biologic treatments, a faster rate of biosimilar adoption, sophisticated drug delivery mechanisms, efforts towards regulatory harmonization for biologics, and strategies for cost optimization in rheumatoid arthritis treatments.
Get A Free Sample Report With In-Depth Market Insights:
Biologic & Biosimilar RA Drugs Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The ongoing increase in healthcare spending is projected to stimulate the expansion of the biologic & biosimilar RA drug market. Healthcare spending refers to the total financial commitment made by individuals, governments, and organizations towards medical goods and services, including expenses for preventing, treating, and managing various health conditions. The application of biologic and biosimilar RA drugs optimizes the management of rheumatoid arthritis, effectively balancing their efficacy with cost-effectiveness for the specialized and often expensive treatments necessary within healthcare expenditure. As an illustration, in November 2023, figures from CIHI, a Canada-based Institute for Health Information health company, indicated that Canada’s total health spending is anticipated to reach $344 billion in 2023, or $8,740 per Canadian. This represents a 2.8% increase in 2023, following a comparatively lower 1.5% growth observed in 2022. Therefore, the rise in healthcare spending is a significant factor propelling the biologic & biosimilar RA drug market.
Biologic & Biosimilar RA Drugs Market Segment Analysis Spotlighting Growth Areas
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Manufacturing: Outsourced, In-House
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Biologic & Biosimilar RA Drugs Market Innovation Trends Shaping Future Development
Leading firms within the biologic & biosimilar RA drugs market are concentrating on creating novel solutions, notably dual-concentration biosimilar formulations, addressing the increasing need for economical, readily available, and patient-centric substitutes for expensive biologics. These dual-concentration biosimilar alternatives provide both high- and low-strength versions that replicate branded biologics, ensuring uninterrupted treatment progression and greater patient convenience when contrasted with conventional single-concentration biologics. As an illustration, during July 2023, Organon, a healthcare enterprise based in the US, and Samsung Bioepis, a biopharmaceutical firm from South Korea, introduced HADLIMA, a biosimilar of Humira (adalimumab), into the US market. Offered in both high and low concentrations, HADLIMA seeks to improve accessibility and economic viability for individuals suffering from autoimmune conditions. This biosimilar is retailed with an 85% price reduction compared to Humira, thereby broadening patient reach. HADLIMA comes equipped with an autoinjector, endorsed by the Arthritis Foundation, and features a patient assistance initiative, HADLIMA For You, which delivers educational content and co-payment aid. Its indications span numerous ailments, such as rheumatoid arthritis and Crohn’s disease. HADLIMA is obtainable in both a citrate-free high concentration (100 mg/mL) and a citrate-containing low concentration (50 mg/mL), ensuring consistent care for patients.
Biologic & Biosimilar RA Drugs Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
View The Full Biologic & Biosimilar RA Drugs Market Report:
Biologic & Biosimilar RA Drugs Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the biologic & biosimilar RA drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model